This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance
by Zacks Equity Research
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business.
Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align
by Zacks Equity Research
Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.
Can These 5 MedTech Stocks Hit Earnings Targets This Season?
by Urmimala Biswas
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Hologic (HOLX) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Hologic (HOLX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Breast Health Performance Likely to Aid Hologic's Q1 Earnings
by Zacks Equity Research
In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.
Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Hologic (HOLX) concluded the recent trading session at $71.77, signifying a -1.35% move from its prior day's close.
Hologic's Q1 Earnings Coming Up: How to Play the Stock?
by Moumi Mondal
In the first quarter of fiscal 2025, HOLX is expected to have benefited from the strength of its core franchises.
Why Hologic (HOLX) Outpaced the Stock Market Today
by Zacks Equity Research
In the closing of the recent trading day, Hologic (HOLX) stood at $71.19, denoting a +1.17% change from the preceding trading day.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic Hits New 52-Week Low: How to Play the Stock Now?
by Moumi Mondal
HOLX touched a new yearly low this week, reflecting market reaction to its mixed Q1 fiscal 2025 results. Still, the stock offers strong rebound potential.
Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Hologic (HOLX) stood at $70.20, denoting a -0.13% change from the preceding trading day.
Hologic (HOLX) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Hologic (HOLX) stood at $72.73, denoting a +0.05% change from the preceding trading day.
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
HOLX Stock Gains Following the Acquisition of Gynesonics
by Zacks Equity Research
Hologic completes the acquisition of Gynesonics, developer of the Sonata System, for approximately $350 million.
Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Hologic (HOLX) concluded the recent trading session at $71.74, signifying a -0.49% move from its prior day's close.
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
by Zacks Equity Research
Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns.
Hologic (HOLX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $72.68 in the latest trading session, marking no change from the prior day.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.